Looking to become the latest addition to the field of treatment options for multiple sclerosis Zinbryta continues to show positive results during clinical trials as it awaits the final steps of the regulatory approval process in the United States and elsewhere.
A patch that uses patients’ own stem cells to protect them from vision loss will soon begin phase 1 trials.
Results from the ATLAS study show that patients with wet AMD treated with Eylea experienced visual and anatomic improvements after 1 year that were sustained after 2 years.
Phase 2a trial of novel topical anti-angiogenic agent regorafenib shows lack of efficacy in neovascular age-related macular degeneration.
According to Henry Kaplan, MD, University of Louisville School of Medicine, ""One has to recognize that there are multiple approaches like gene therapy, neuro protection, stem cell transplantation, and pharmacologic manipulation of other genes really holds the greatest benefit in terms of trying to reverse the inevitable loss of vision,"
Henry Kaplan, MD, KY Lions Eye Center, University of Louisville School of Medicine, is focusing his efforts on figuring out how to preserve or recover lost central vision in patients with retinitis pigmentosa.
Previous research has red-flagged migraines as being associated with silent brain infarcts and white matter hyperintensities (WMH). However, a team of doctors in Denmark found zero evidence to back that up.
The distance a COPD patient can walk is a measure of future health. Rehabilitation that increases walking by 600 steps is a sign of success.
Hepatitis C infection mortality in 2013 surpassed the total combined number of deaths from 60 other infectious illnesses, the CDC reports.